Follow-up surveillance strategies for genitourinary malignancies

Cancer

Volumn 94, Issue 11, 2002, Pages 2892-2905

  Evans, Christopher P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bladder cancer; Cancer surveillance; Prostate cancer; Renal cell cancer; Testicular cancer; Urologic cancer follow up

Indexed keywords

ARTICLE; BLADDER CANCER; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; COST BENEFIT ANALYSIS; ECONOMIC ASPECT; FOLLOW UP; HUMAN; KIDNEY CANCER; MEDICARE; MORTALITY; PRIORITY JOURNAL; PROSTATE CANCER; RADIOGRAPHY; REIMBURSEMENT; TESTIS CANCER; UROGENITAL TRACT CANCER;

CLINICAL TRIALS; COSTS AND COST ANALYSIS; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; UNITED STATES; UROGENITAL NEOPLASMS;

EID: 0036604461     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10525     Document Type: Article

References (63)

1. The ASCO experience with evidence-based clinical practice guidelines
2. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results
3. How tumor stage affects American urologists' surveillance strategies after prostate cancer surgery
4. Current followup strategies after radical prostatectomy: A survey of American Urological Association urologists
5. The age of the urologist affects the postoperative care of prostate carcinoma patients
6. Follow-up in prostate cancer patients: Which parameters are necessary?
7. Natural history of progression after PSA elevation following radical prostatectomy
8. Value of digital rectal exam after radical prostatectomy in detecting recurrence
9. Is there a role for digital rectal examination in the followup of patients after radical prostatectomy?
10. Efficacy of digital rectal examination after radiotherapy for prostate cancer
11. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy
12. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy
13. Clinical and molecular followup after radical retropubic prostatectomy
14. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy
15. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients
16. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy
17. Fluorine-18-fiuorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy
18. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?
19. Radiotherapy for PSA recurrence after radical prostatectomy
20. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years
21. Radiation therapy (RT) after prostatectomy: The case for salvage therapy as opposed to adjuvant therapy
22. Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate specific antigen
23. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
24. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer
25. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial
26. Follow-up after radical prostatectomy or radiation therapy for prostate cancer
27. The treated natural history of high risk superficial bladder cancer: 15-Year outcome
28. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years
29. Late recurrence and progression after a long tumor-free period in primary Ta and T1 bladder cancer
30. Urine cytology in the detection of bladder cancer: A critical approach
31. Urine based markers of urological malignancy
32. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: Comparison with urinary cytology and BTA test
33. Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer
34. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?
35. A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder
36. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma
37. A new protocol for the followup of renal cell carcinoma based on pathological stage
38. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup
39. Changing trends in partial nephrectomy at Walter Reed Army Medical Center
40. Open surgical partial nephrectomy
41. Prospective analysis of multifocality in renal cell carcinoma: Influence of histological pattern, grade, number, size, volume and deoxyribonucleic acid ploidy
42. Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma
43. Identifying patients with low-risk clinical stage I nonseminomatous testicular tumors who should be treated by surveillance
44. Cost-effective strategies for the follow-up of patients with germ cell tumors
45. Progression detection of stage I nonseminomatous testis cancer on surveillance: Implications for the followup protocol
46. Editorial comment
47. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989
48. Late relapse of clinical stage I testicular cancer
49. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients
50. FDG PET for detection and therapy control of metastatic germ cell tumor
51. Clinical characteristics of metachronous bilateral testicular tumors in the chemotherapeutic era
52. Risk of second malignant neoplasms among long-term survivors of testicular cancer
53. Second malignancies following pure seminoma
54. Proposal for changes in cystoscopic follow-up of patients with low-grade pTa bladder tumor
55. Follow-up after cystectomy for carcinoma of the bladder
56. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
57. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors
58. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse
59. Follow-up after partial or total nephrectomy for renal cell carcinoma
60. Heterogeneity of cancer surveillance practices among medical oncologists in Washington and Oregon